Oxylabs becomes Lithuania’s second most valuable private company at $3.6B
For 10 years, Oxylabs turned away outside investors, building an unglamorous proxy business into a company generating hundreds…
Read the full articleYou might also wanna read
New Lithuanian unicorn: Oxylabs ends bootstrapped streak after securing €113.6 million at €3.1 billion valuation
Oxylabs, a Vilnius-based data infrastructure platform, has secured €113.6 million ($130 million) in funding from Warburg Pincus, valuing the
Evonik Aktie: 650 Millionen EBITDA im Q2 erwartet
Evonik schaltet in den Angriffsmodus. Der Spezialchemie-Konzern investiert massiv in den USA. Parallel dazu hebt die Führung ihre Gewinnziel
Not Found
Some startups valued at more than $1bn may have raised no money because they did not need it. But others may be struggling to justify mythic
Invest Europe: Venture capital reaches second-highest level on record
Invest Europe has published its latest report, Transaction Value: Private Capital Analysis, examining private capital investment across Euro
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
This could be a key move for future growth.
Business Watch: Evonik announces 3,200 job cuts; AbbVie acquires Apogee for $11 billion
Here’s what we’re watching in the chemical and pharmaceutical industries this week
cen.acs.org·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.